Clover Biopharmaceuticals Ltd. (HK:2197) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clover Biopharmaceuticals announced promising results from its Phase I trial of the RSV vaccine candidate SCB-1019, demonstrating comparable immunogenicity to GSK’s AREXVY while showing significantly lower adverse event rates. The vaccine, based on Clover’s Trimer-Tag technology, holds potential for broader immune response and better tolerability, paving the way for further trials in 2025. This development could enhance Clover’s position in the competitive vaccine market, attracting keen interest from investors and market watchers.
For further insights into HK:2197 stock, check out TipRanks’ Stock Analysis page.